drugset / Trial / NCT00714597
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary objective was to compare the efficacy of once daily \[q.d\] subcutaneous \[s.c.\] injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the primary prevention of Venous Thromboembolic Events \[VTE\] in patients hospitalized for acute medical illness. The secondary objectives were to evaluate the safety of AVE5026 and to document AVE5026 exposure in this population.
Timeline
- Start
- 2008-07
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enoxaparin sodium | Other / unclassified | 20 mg | Subcutaneous |
| Comparator | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Semuloparin | Other / unclassified | 10 mg | Subcutaneous |
| Subject | Semuloparin | Other / unclassified | 20 mg | Subcutaneous |